← Leaderboards
Viji Shridhar
Mayo Clinic Rochester
$3,298,125
Attributed
$4,525,944
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $592.4K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,525,944 · 5
By mechanism
R01$2,489,750 · 2
P50$1,219,396 · 1
R21$816,798 · 2
Top collaborators
- Keith C Bible5 shared
- Jeremy Chien4 shared
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseIn VitroMalignant Neoplasm Of OvaryPharmaceutical PreparationsResistanceCancer Cell LineMalignant NeoplasmsMediatingBaseTumorCytotoxicityResearch StudyCisplatinCancer TherapyDiagnosisInsightWomanPlatinumAnimal ModelDown-RegulationScreening ProcedureCell LineClinical RemissionIn Vivo
Grant awards (17)
CCNE1 is synthetically lethal with drug induced nuclear Cathepsin L (nCTSL)$412,429
R21 · FY2025 · CA · contact PI
PG545 synergizes with PARP inhibitors in ovarian cancer to disrupt DNA repair through modulation of DEK-RAD51 axis$218,538
R21 · FY2023 · CA · contact PI
PG545 synergizes with PARP inhibitors in ovarian cancer to disrupt DNA repair through modulation of DEK-RAD51 axis$185,831
R21 · FY2022 · CA · contact PI
Flavopiridol Reverses Platinum Resistance in Ovarian Cancer$219,848
P50 · FY2013 · CA
Regulation of Serine Protease HtrA1 and Chemoresponse$304,127
R01 · FY2012 · CA · contact PI
Flavopiridol Reverses Platinum Resistance in Ovarian Cancer$238,831
P50 · FY2012 · CA
Regulation of Serine Protease HtrA1 and Chemoresponse$304,127
R01 · FY2011 · CA · contact PI
Flavopiridol Reverses Platinum Resistance in Ovarian Cancer$233,601
P50 · FY2011 · CA
Regulation of Serine Protease HtrA1 and Chemoresponse$313,533
R01 · FY2010 · CA · contact PI
Flavopiridol Reverses Platinum Resistance in Ovarian Cancer$248,246
P50 · FY2010 · CA
Regulation of Serine Protease HtrA1 and Chemoresponse$313,533
R01 · FY2009 · CA · contact PI
Flavopiridol Reverses Platinum Resistance in Ovarian Cancer$278,870
P50 · FY2009 · CA
Regulation of Serine Protease HtrA1 and Chemoresponse$305,050
R01 · FY2008 · CA · contact PI
Role of HSulf-1 Loss in Apoptosis and Drug Resistance$229,365
R01 · FY2007 · CA · contact PI
Role of HSulf-1 Loss in Apoptosis and Drug Resistance$236,215
R01 · FY2006 · CA · contact PI
Role of HSulf-1 Loss in Apoptosis and Drug Resistance$241,900
R01 · FY2005 · CA
Role of HSulf-1 Loss in Apoptosis and Drug Resistance$241,900
R01 · FY2004 · CA